# A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects

> **NCT00301483** · PHASE2 · UNKNOWN · sponsor: **Biopure Corporation** · enrollment: 53 (estimated)

## Conditions studied

- Wounds and Injuries

## Interventions

- **DRUG:** Hemoglobin-based oxygen carrier-201 (HBOC 201)
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT00301483
- **Lead sponsor:** Biopure Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-07
- **Primary completion:** 2008-09
- **Final completion:** 2008-12
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2008-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00301483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00301483, "A Single Site Safety and Tolerability Study of HBOC-201 in Trauma Subjects". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00301483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*